(MedPage Today) — Canakinumab (Ilaris) may be the better option than anakinra (Kineret) when treating the rare disease called VEXAS syndrome with an interleukin-1 (IL-1) inhibitor, a multinational study indicated.
Among 47 VEXAS patients treated…
Source link : https://www.medpagetoday.com/rheumatology/generalrheumatology/117612
Author :
Publish date : 2025-09-23 21:29:00
Copyright for syndicated content belongs to the linked Source.
